Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - BetterLife Pharma (CSE: BETR), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.
Dates: | Tuesday April 25, 2023-Wednesday April 26, 2023 |
Time: | 8:30 AM-4:30 PM ET |
Location: | Metro Toronto Convention Centre, North Building 255 Front St W Toronto, Ontario M5V 2W6 |
Dr. Ahmad Doroudian & Dr. Hooshmand Sheshbaradaran will be speaking at 3:30 PM ET on April 26th. Interested parties can register to attend here.
Members of the BetterLife Pharma management will also be taking meetings throughout the day. Take advantage of the opportunity and reach out to the team.
To register and access, please follow this link.
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be potentially self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife's pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.
About the Conference:
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
About Bloom Burton & Co.:
Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, as well as advisory on direct investing, company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).
For further information:
David Melles
Investor Relations Manager
778.887.1928
David.Melles@blifepharma.com
溫哥華,不列顛哥倫比亞省-(Newsfile Corp.-2023年4月24日)-BetterLife製藥公司(CSE:BETR),一家專注於精神障礙尖端治療方法的開發和商業化的新興生物技術公司,將參加2023年Bloom Burton&Co.Healthcare投資者大會,該會議將於4月25日和26日在多倫多大都會會議中心。
日期: | 2023年4月25日星期二-2023年4月26日星期三 |
時間: | 東部時間上午8:30-下午4:30 |
位置: | 多倫多大都會會議中心 北街255號樓前西街 安大略省多倫多 M5V 2W6 |
Ahmad Doroudian博士和Hooshmand Sheshbaradaran博士將於美國東部時間4月26日下午3:30發表講話。有興趣的人可以在這裡註冊參加。
BetterLife Pharma管理層的成員也將全天開會。利用這個機會,與團隊接觸。
要註冊和訪問,請點擊此鏈接.
關於BetterLife製藥公司
BetterLife製藥公司是一家新興的生物技術公司,主要致力於開發和商業化兩種化合物BETR-001和BETR-002,用於治療神經精神和神經疾病。Betr-001處於臨床前研究和IND使能研究中,是一種開發中的非致幻和非受控LSD衍生物,其獨特之處在於它不受監管,因此可以潛在地自我給藥。BetterLife的BETR-001合成專利消除了管理障礙,其正在申請的成分和使用方法專利涵蓋了治療嚴重抑鬱症、焦慮症和神經病理性疼痛以及其他神經精神和神經性疾病。Betr-002正在進行臨床前和IND的研究,它是基於厚朴酚的,和厚朴酚是厚朴樹皮的有效抗焦慮成分。BetterLife正在申請的使用方法和配方專利涵蓋了治療焦慮症相關疾病,包括對苯二氮卓的依賴。BetterLife還擁有一種治療新冠肺炎等病毒感染的候選藥物,並正在尋找進一步發展的戰略替代藥物。
關於會議:
作者聲明:Healthcare投資者大會匯聚了對加拿大醫療行業最新發展感興趣的美國、加拿大和國際投資者.與會者將有機會通過演講和私人會議獲得加拿大主要上市公司和私人公司的最新公司資訊.
布魯姆·伯頓公司簡介:
布魯姆·伯頓公司是一家致力於為投資者和公司加速醫療保健領域回報的公司.布魯姆·伯頓擁有一支由醫療、科學、工業和資本市場專業人士組成的經驗豐富的團隊,他們的勤奮程度與我們的創意和創業方法相結合,幫助我們的客戶實現正確的貨幣化活動。布魯姆·伯頓及其附屬公司提供融資、並購諮詢、股票研究、商業戰略和科學諮詢,以及直接投資、公司創建和孵化服務的諮詢。Bloom Burton證券公司是加拿大投資行業監管組織(IIROC)的成員,也是加拿大投資者保護基金(CIPF)的成員.
有關更多資訊,請訪問:
David·梅爾斯
投資者關係經理
778.887.1928
郵箱:David.Melle@blifepharma.com